The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome

Autor:	John W.M. Martens, Michael A. den Bakker, Ingeborg E. de Kruijff, Marion E. Meijer-van Gelder, Renée Foekens, Antoinette Hollestelle, Stefan Sleijfer, Anita M. A. C. Trapman-Jansen, John A. Foekens, Marcel Smid, Esther Oomen-de Hoop, Carolien H.M. van Deurzen, Anna. M. Timmermans
Přispěvatelé:	Medical Oncology, Pathology
Jazyk:	angličtina
Rok vydání:	2018
Předmět:	0301 basic medicine Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment tamoxifen resistance Estrogen receptor Article 03 medical and health sciences 0302 clinical medicine Breast cancer breast cancer SDG 3 - Good Health and Well-being Internal medicine CD146 EMT prognostic marker Progesterone receptor medicine skin and connective tissue diseases business.industry Cancer Retrospective cohort study medicine.disease 030104 developmental biology 030220 oncology & carcinogenesis business Adjuvant Tamoxifen medicine.drug
Zdroj:	Cancers Cancers, 10(5):134. Multidisciplinary Digital Publishing Institute (MDPI) Cancers; Volume 10; Issue 5; Pages: 134
ISSN:	2072-6694
Popis:	CD146, involved in epithelial-to-mesenchymal transition (EMT), might affect cancer aggressiveness. We here investigated the prevalence of CD146 expression in breast cancer subtypes, its relation to prognosis, the relation between CD146 and EMT and the outcome to tamoxifen. Primary breast cancer tissues from 1342 patients were available for this retrospective study and immunohistochemically stained for CD146. For survival analyses, pure prognosis was studied by only including lymph-node negative patients who did not receive (neo)adjuvant systemic treatment (n = 551). 11% of the tumors showed CD146 expression. CD146 expression was most prevalent in triple-negative cases (64%, p < 0.001). In univariable analysis, CD146 expression was a prognostic factor for both metastasis-free survival (MFS) (p = 0.020) and overall survival (OS) (p = 0.037), but not in multivariable analysis (including age, tumor size, grade, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67). No correlation between CD146 and EMT nor difference in outcome to first-line tamoxifen was seen. In this large series, our data showed that CD146 is present in primary breast cancer and is a pure prognostic factor for MFS and OS in breast cancer patients. We did not see an association between CD146 expression and EMT nor on outcome to tamoxifen.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50425312798e61d53883f66e70630fa6 http://europepmc.org/articles/PMC5977107 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.